Credit Suisse AG Raises Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

Credit Suisse AG lifted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 36.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 362,849 shares of the company's stock after buying an additional 96,333 shares during the quarter. Credit Suisse AG owned approximately 0.64% of Health Catalyst worth $4,234,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Fairfield Bush & CO. purchased a new stake in Health Catalyst in the first quarter valued at approximately $25,000. Macquarie Group Ltd. purchased a new stake in Health Catalyst in the second quarter valued at approximately $26,000. Point72 Hong Kong Ltd purchased a new stake in Health Catalyst in the first quarter valued at approximately $33,000. WealthPlan Investment Management LLC purchased a new stake in Health Catalyst during the first quarter worth approximately $39,000. Finally, US Bancorp DE grew its stake in Health Catalyst by 36.5% during the first quarter. US Bancorp DE now owns 4,260 shares of the company's stock worth $50,000 after buying an additional 1,139 shares during the period. 86.63% of the stock is currently owned by hedge funds and other institutional investors.

Several equities research analysts have issued reports on the stock. Raymond James downgraded shares of Health Catalyst from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 10th. Canaccord Genuity Group decreased their price objective on shares of Health Catalyst from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday. Cantor Fitzgerald assumed coverage on shares of Health Catalyst in a research note on Tuesday, August 1st. They set an "overweight" rating and a $16.00 price objective for the company. Finally, Guggenheim downgraded shares of Health Catalyst from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 10th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $14.55.

Read Our Latest Stock Report on Health Catalyst

In related news, CAO Jason Alger sold 2,370 shares of the company's stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $11.84, for a total value of $28,060.80. Following the sale, the chief accounting officer now directly owns 60,068 shares of the company's stock, valued at $711,205.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 6,014 shares of company stock valued at $70,529 over the last ninety days. Corporate insiders own 2.70% of the company's stock.

HCAT opened at $11.46 on Thursday. The stock has a market capitalization of $652.76 million, a PE ratio of -4.28 and a beta of 1.27. The firm's fifty day moving average price is $12.46 and its 200 day moving average price is $12.31. The company has a debt-to-equity ratio of 0.58, a current ratio of 4.74 and a quick ratio of 4.74. Health Catalyst, Inc. has a 12-month low of $6.40 and a 12-month high of $15.87.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.09. The firm had revenue of $73.21 million for the quarter, compared to analysts' expectations of $72.67 million. Health Catalyst had a negative net margin of 51.76% and a negative return on equity of 16.49%. As a group, research analysts expect that Health Catalyst, Inc. will post -1 EPS for the current fiscal year.

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Health Catalyst, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.

While Health Catalyst currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.